Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11959477 | 0.85 | CES1 (0.53) | DAGLAMEN1KMT2A | |
| SCHEMBL10318323 | 0.81 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL11564835 | 0.80 | CYP1A2 (0.50) | LMNASMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL3384965 | 0.79 | HRH3 (0.56) | SMN1; SMN2MAPTRAB9AALDH1A1MEN1 | |
| SCHEMBL10317838 | 0.78 | RAB9A (0.50) | LMNASMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL10316969 | 0.74 | ALDH1A1 (0.50) | LMNASMN1; SMN2MAPTALDH1A1NMT2 | |
| SCHEMBL10351448 | 0.73 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL10317006 | 0.73 | SMN1; SMN2 (0.62) | LMNASMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL15932112 | 0.73 | CYP1A2 (0.46) | SMN1; SMN2MAPTRAB9AALDH1A1POLB | |
| SCHEMBL9714181 | 0.72 | CYP1A2 (0.51) | SMN1; SMN2MAPTRAB9AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815920-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8669246-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-09-05 | — | — | US | disclosed |
| WO-2011037192-A1 | SUBSTITUTED AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | DAGLA 1228/4885LMNA 557/4885SMN1; SMN2 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.